drugset / Trial / NCT03053622
A Study of Mirikizumab (LY3074828) Injection in Healthy Participants
RandomizedParallel-groupOpen-labelBasic science
Summary
This study is conducted to compare how much mirikizumab, in two different formulations, is absorbed into the bloodstream and how long the body takes to get rid of it, when given as an injection under the skin or into the veins. Side effects of the injection will be collected. Each participant will be in the study for about 18 weeks, including screening.
Timeline
- Start
- 2017-04-24
- Primary completion
- 2018-04-03
- Completion
- 2018-04-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirikizumab | Monoclonal antibody | 250 mg | Subcutaneous |
Indications
No indication recorded.